AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML
Leukemia, Published online: 09 May 2024; doi:10.1038/s41375-024-02255-1AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML (Source: Leukemia)
Source: Leukemia - May 9, 2024 Category: Hematology Authors: Ece Canan Sayitoglu Bogdan A. Luca Allison Paige Boss Benjamin Craig Thomas Robert Arthur Freeborn Molly Javier Uyeda Pauline Ping Chen Yusuke Nakauchi Colin Waichler Norman Lacayo Rosa Bacchetta Ravindra Majeti Andrew J. Gentles Alma-Martina Cepika Maria Source Type: research
PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL
Leukemia, Published online: 09 May 2024; doi:10.1038/s41375-024-02271-1PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL (Source: Leukemia)
Source: Leukemia - May 9, 2024 Category: Hematology Authors: Mustafa Farhat Wayne Croft Helen M. Parry Kriti Verma Francesca A. M. Kinsella Jinsong Xu David Bone Tina McSkeane Shankara Paneesha Guy Pratt Paul Moss Jianmin Zuo Source Type: research
Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children
Decitabine (DAC), a DNA methyltransferase inhibitor, has shown efficacy combined with chemotherapy for relapsed or refractory (R/R) acute myeloid leukemia (AML) in adults, but less is known about its efficacy ... (Source: Clinical Epigenetics)
Source: Clinical Epigenetics - May 9, 2024 Category: Research Authors: Na Zhang, Hong Li, Dan Wang, Zhen Wang, Jia-Shi Zhu, Kai Chen, Hui Jiang, Jing-Bo Shao and Cheng Cai Tags: Research Source Type: research
Clinical prognostic value of different NPM1 mutations in acute myeloid leukemia patients
Conclusions: No significant difference was observed in OS and EFS between patients withNPM1A − type mut andNPM1non − A−type mut. However, types ofNPM1 mutations and the status ofFLT3-ITD mutations may jointly have an impact on the prognosis of AML patients. (Source: Annals of Hematology)
Source: Annals of Hematology - May 9, 2024 Category: Hematology Source Type: research
PhALLCON Soars to New Heights —Faster, Stronger, but Better?
In this issue of JAMA, Jabbour and colleagues report results from the interim analysis of the PhALLCON randomized trial with ponatinib vs imatinib, combined with reduced-intensity chemotherapy. They found ponatinib to have superior efficacy and a comparable safety profile for frontline treatment of adults with newly diagnosed Philadelphia chromosome –positive acute lymphoblastic leukemia (Ph+ ALL). On the heels of these results, the US Food and Drug Administration granted ponatinib accelerated approval for this indication on March 19, 2024. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - May 9, 2024 Category: General Medicine Source Type: research
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome –Positive ALL
This randomized trial assesses the effect of ponatinib vs imatinib combined with low-intensity chemotherapy on disease remission in adults with newly diagnosed Philadelphia chromosome –positive acute lymphoblastic leukemia (ALL). (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - May 9, 2024 Category: General Medicine Source Type: research
Acute Myelomonocytic Leukemia Presenting as Fournier's Gangrene
CONCLUSIONS: This case highlights the challenges in the diagnosis and management of acute leukemia in the setting of a concomitant life-threatening soft tissue infection, as both the hematologic disease and treatment thereof can exacerbate infectious complications.PMID:38718243 (Source: WMJ)
Source: WMJ - May 8, 2024 Category: General Medicine Authors: Sofie Kjellesvig Emelyn Zaworski Antoine N Saliba Source Type: research
JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib
CONCLUSIONS: Based on these findings, JAK2 levels may be a potential indicator for evaluating treatment response on imatinib due to its role in the pathophysiology of CML.PMID:38716474 | PMC:PMC11074917 | DOI:10.1155/2024/2906566 (Source: Disease Markers)
Source: Disease Markers - May 8, 2024 Category: Laboratory Medicine Authors: Indra Wijaya Muhammad H Bashari Lelani Reniarti Anita Rahmawati Rully M A Roesli Source Type: research
Acute Myelomonocytic Leukemia Presenting as Fournier's Gangrene
CONCLUSIONS: This case highlights the challenges in the diagnosis and management of acute leukemia in the setting of a concomitant life-threatening soft tissue infection, as both the hematologic disease and treatment thereof can exacerbate infectious complications.PMID:38718243 (Source: WMJ)
Source: WMJ - May 8, 2024 Category: General Medicine Authors: Sofie Kjellesvig Emelyn Zaworski Antoine N Saliba Source Type: research
JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib
CONCLUSIONS: Based on these findings, JAK2 levels may be a potential indicator for evaluating treatment response on imatinib due to its role in the pathophysiology of CML.PMID:38716474 | PMC:PMC11074917 | DOI:10.1155/2024/2906566 (Source: Disease Markers)
Source: Disease Markers - May 8, 2024 Category: Laboratory Medicine Authors: Indra Wijaya Muhammad H Bashari Lelani Reniarti Anita Rahmawati Rully M A Roesli Source Type: research
Acute Myelomonocytic Leukemia Presenting as Fournier's Gangrene
CONCLUSIONS: This case highlights the challenges in the diagnosis and management of acute leukemia in the setting of a concomitant life-threatening soft tissue infection, as both the hematologic disease and treatment thereof can exacerbate infectious complications.PMID:38718243 (Source: WMJ)
Source: WMJ - May 8, 2024 Category: General Medicine Authors: Sofie Kjellesvig Emelyn Zaworski Antoine N Saliba Source Type: research
JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib
CONCLUSIONS: Based on these findings, JAK2 levels may be a potential indicator for evaluating treatment response on imatinib due to its role in the pathophysiology of CML.PMID:38716474 | PMC:PMC11074917 | DOI:10.1155/2024/2906566 (Source: Disease Markers)
Source: Disease Markers - May 8, 2024 Category: Laboratory Medicine Authors: Indra Wijaya Muhammad H Bashari Lelani Reniarti Anita Rahmawati Rully M A Roesli Source Type: research
Acute Myelomonocytic Leukemia Presenting as Fournier's Gangrene
CONCLUSIONS: This case highlights the challenges in the diagnosis and management of acute leukemia in the setting of a concomitant life-threatening soft tissue infection, as both the hematologic disease and treatment thereof can exacerbate infectious complications.PMID:38718243 (Source: WMJ)
Source: WMJ - May 8, 2024 Category: General Medicine Authors: Sofie Kjellesvig Emelyn Zaworski Antoine N Saliba Source Type: research
JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib
CONCLUSIONS: Based on these findings, JAK2 levels may be a potential indicator for evaluating treatment response on imatinib due to its role in the pathophysiology of CML.PMID:38716474 | PMC:PMC11074917 | DOI:10.1155/2024/2906566 (Source: Disease Markers)
Source: Disease Markers - May 8, 2024 Category: Laboratory Medicine Authors: Indra Wijaya Muhammad H Bashari Lelani Reniarti Anita Rahmawati Rully M A Roesli Source Type: research
Acute Myelomonocytic Leukemia Presenting as Fournier's Gangrene
CONCLUSIONS: This case highlights the challenges in the diagnosis and management of acute leukemia in the setting of a concomitant life-threatening soft tissue infection, as both the hematologic disease and treatment thereof can exacerbate infectious complications.PMID:38718243 (Source: WMJ)
Source: WMJ - May 8, 2024 Category: General Medicine Authors: Sofie Kjellesvig Emelyn Zaworski Antoine N Saliba Source Type: research
